KAIROS PHARMA LTD Stock Price, News & Analysis

Kairos Pharma (NYSE American: KAPA) has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City. The company's CEO and Chairman, John Yu, MD, will be available for one-on-one meetings with interested parties from 9:00 A.M. to 3:00 P.M. (ET). Interested participants can register for meetings by contacting John Perez at jperez@dboralcapital.com.

Kairos Pharma (NYSE American: KAPA) has announced its upcoming presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, scheduled for May 30-June 3, 2025, in Chicago. The company will present a poster on June 2 titled 'Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity.' CEO John Yu expressed enthusiasm about sharing data on their platform assets at this prestigious oncology meeting, highlighting KROS 101's potential in optimizing cancer treatment.

Kairos Pharma (NYSE: KAPA) provided a stockholder update highlighting its clinical progress and future outlook. The company is conducting two clinical trials for its lead drug ENV105: a Phase 2 trial for prostate cancer and a Phase 1 trial for EGFR-dependent non-small cell lung cancer. The company received an $876,000 Department of Defense grant for biomarker studies.

Trial sites have expanded beyond Cedars Sinai Hospital to include the University of Utah and City of Hope, with safety and interim efficacy results expected by Q2 2025. The company is also developing KROS101, a GITR ligand small molecule agonist for cancer treatment, with data presented at multiple scientific conferences.

The company maintains a strong financial position through recent private placement and non-dilutive funding, with research coverage from multiple investment banks including EF Hutton and HC Wainwright.

Kairos Pharma (NYSE American: KAPA) has received a $876,000 Department of Defense grant to support research identifying biomarkers in non-small cell lung cancer patients who develop resistance to osimertinib treatment. The grant was awarded to Cedars-Sinai Medical Center to support research in Dr. Neil Bhowmick's laboratory.

The company is currently conducting a Phase 1 trial of its lead compound ENV105 in combination with osimertinib for EGFR-driven lung cancer patients who fail to respond to single-agent osimertinib. The funded research aims to develop strategies for early detection of drug resistance and identify patients who would benefit most from ENV105 treatment, potentially improving overall survival and quality of life for patients.

Kairos Pharma (NYSE: KAPA) has completed the safety lead-in phase of its Phase 2 clinical trial for ENV105 in treating metastatic, castration-resistant prostate cancer. The trial combines ENV105 with apalutamide, a standard prostate cancer treatment.

The study consists of two parts: the completed safety lead-in and an ongoing randomized portion comparing apalutamide alone versus apalutamide with ENV105. The company expects to release safety and efficacy data from the safety arm in the first half of 2025.

Patient enrollment continues for the randomization arm at cancer centers in Los Angeles and Salt Lake City. The trial includes biomarker validation to identify patients most likely to benefit from the combination therapy. The study is supported by Kairos Pharma and a National Cancer Institute grant.

CEO.CA, a leading investor social network for venture stocks, has released an exclusive interview with John Yu, CEO & Chairman of Kairos Pharma (NYSE: KAPA), discussing their cancer treatment ENV105. The interview, part of CEO.CA's 'Inside the Boardroom' series, focuses on the company's recent funding and its impact on research acceleration.

The interview is available on CEO.CA's platform and YouTube channel, which serves millions of visitors annually as one of Canada's most popular financial websites. The platform, founded in 2012 and now a subsidiary of EarthLabs, Inc., offers investors worldwide a space to connect, share knowledge, and access information about stocks, commodities, and emerging companies.

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has announced its participation in several key scientific and industry events. The company presented their novel GITR Agonist KROS 101 research at the Society for Immunotherapy of Cancer Spring Scientific Meeting on March 12, 2025, and attended the BIO Europe conference in Milan.

Upcoming events include participation in the Fierce Pharma Engage Business Development meeting in San Diego (April 29-May 1) and a presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (May 20-June 5). The company recently received research coverage initiation from Maxim Group on March 27.

CEO John Yu highlighted that Phase 2 trials for ENV105 are advancing, while their KROS platform shows promise in cancer immunotherapy, demonstrating the company's commitment to oncology program development and shareholder value creation.

Kairos Pharma (NYSE American: KAPA) has published peer-reviewed research revealing a potential breakthrough in treating drug resistance in non-small cell lung cancer (NSCLC). The study, published in Drug Resistance Updates, demonstrates that CD105 (endoglin) plays a important role in resistance to osimertinib, a frontline NSCLC treatment.

The research shows that ENV105 (carotuximab), a CD105-neutralizing antibody, successfully restored treatment sensitivity to EGFR-targeted therapies in preclinical models. The combination of osimertinib with ENV105 reinstated susceptibility to EGFR inhibition through metabolic reprogramming and enhanced chromatin accessibility.

The global NSCLC treatment market is projected to reach $45 billion by 2030. Kairos Pharma is currently conducting clinical trials to evaluate this therapy in EGFR-driven lung cancer patients.

Kairos Pharma (NYSE: KAPA) presented preclinical data on two investigational compounds at the AACR IO conference in Los Angeles (Feb 23-26, 2025). The first compound, KROS 101, a GITR agonist, showed significant tumor growth inhibition in melanoma models and demonstrated superior anti-tumor activity compared to TRX518. It increased helper and cytotoxic T cell proliferation while preventing T cell exhaustion in tumors.

The second compound, KROS 401, a peptide inhibitor, showed promise in reprogramming macrophages to inhibit tumor growth. Studies revealed anti-tumor effects in glioma-bearing mice by decreasing M2 macrophages that typically facilitate tumor growth. The research indicates potential therapeutic applications for both melanoma and glioblastoma treatment.